Drug Approval | July 22, 2024
Briefs: Zydus Lifesciences and Divi's Laboratories
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Finance Minister Nirmala Sitharaman is set to present the full budget for the current financial year on July 23
The inspection closed with five observations which were more of procedural changes with none of these related to data integrity
ProtocolCopilot leverages advanced artificial intelligence to streamline the process of understanding and adhering to clinical research protocols
_256_384.jpg)
€ 6.6 million investment at Nantong site expands production capabilities for cell culture media
The company will address these observations within the stipulated timeline
Directs officials to ensure that challenges hampering their effective implementation are resolved early in coordination with states
The My Green Lab Certification is the gold standard for laboratory sustainability practices worldwide
Sacubitril and Valsartan combination is used to treat chronic heart failure in adults
Acquisition provides Ligand with the royalty rights to QARZIBA, a highly differentiated, commercial oncology drug marketed in 35 countries by global pharmaceutical company Recordati S.p.A.
Subscribe To Our Newsletter & Stay Updated
